|
30 Dec 2019 |
Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
|
30 Dec 2019 |
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
21 Dec 2019 |
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
|
|
21 Dec 2019 |
Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis
|
|
21 Dec 2019 |
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
|
|
20 Dec 2019 |
Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia
|
|
20 Dec 2019 |
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
|
|
20 Dec 2019 |
Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
|
|
20 Dec 2019 |
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
|
|
18 Dec 2019 |
DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease
|
|
16 Dec 2019 |
Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
|
|
13 Dec 2019 |
BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
|
|
11 Dec 2019 |
Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
|
|
10 Dec 2019 |
BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors
|
|
10 Dec 2019 |
ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
|
|
08 Dec 2019 |
Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology
|
|
08 Dec 2019 |
Grifols presents its latest Alzheimer's clinical trial data
|
|
06 Dec 2019 |
Fibriant Expands License Adding Recombinant Human (pro)thrombin to Existing Recombinant Fibrinogen Capability
|
|
05 Dec 2019 |
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
|
|
05 Dec 2019 |
Arecor Announces Positive Headline Results for the First Phase I Clinical Trial of AT247, a Novel Ultra Rapid Acting Formulation of Insulin
|
|
05 Dec 2019 |
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
|
|
04 Dec 2019 |
Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus US Lantus®
|
|
04 Dec 2019 |
Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
|
|
04 Dec 2019 |
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
|
|
03 Dec 2019 |
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
|
